Neurocrine Biosciences to Present at the SVB Securities Global Biopharma Conference

On February 14, 2023, at 12:00 p.m. Eastern Time, Neurocrine Biosciences (NASDAQ: NBIX) will present at the virtual SVB Securities Global Biopharma Conference.

Rhea-AI Summary

On February 14, 2023, at 12:00 p.m. Eastern Time, Neurocrine Biosciences (NASDAQ: NBIX) will present at the virtual SVB Securities Global Biopharma Conference. The presentation will be led by CEO Kevin Gorman and CFO Matt Abernethy. Interested parties can access the live webcast on the company’s website under the Investors section. A replay will be available approximately one hour post-event and archived for one month. Neurocrine Biosciences focuses on developing treatments for under-addressed neurological, neuroendocrine, and neuropsychiatric disorders, with a diverse portfolio and 12 mid-to-late-stage clinical programs.

Argus Session date unavailable

+0.65% session move Open Argus

Details

News Market Reaction – NBIX

The recorded move for NBIX in the trading session of this news was +0.65%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, Feb. 7, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the virtual SVB Securities Global Biopharma Conference at 12:00 p.m. Eastern Time on Tuesday, February 14, 2023. Kevin Gorman, Chief Executive Officer, and Matt Abernethy, Chief Financial Officer, will present at the conference.       

The live presentation will be webcast and may be accessed on the Company's website under Investors at www.neurocrine.com. A replay of the presentation will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.

About Neurocrine Biosciences
Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson's disease, endometriosis* and uterine fibroids*, and 12 mid-to-late-stage clinical programs in multiple therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn. (*in collaboration with AbbVie)

View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-at-the-svb-securities-global-biopharma-conference-301741116.html

SOURCE Neurocrine Biosciences, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is Neurocrine Biosciences presenting at the SVB Securities Global Biopharma Conference?

Neurocrine Biosciences will present on February 14, 2023, at 12:00 p.m. Eastern Time.

Who will represent Neurocrine Biosciences at the conference?

CEO Kevin Gorman and CFO Matt Abernethy will represent Neurocrine Biosciences.

How can I access the Neurocrine Biosciences presentation?

The presentation can be accessed live via the company's website under the Investors section.

Will there be a replay of the Neurocrine Biosciences presentation?

Yes, a replay will be available approximately one hour after the event and will be archived for one month.

What is the focus of Neurocrine Biosciences?

Neurocrine Biosciences focuses on developing treatments for neurological, neuroendocrine, and neuropsychiatric disorders.